Evaluation of Genetic Factors for Warfarin Dose Prediction (Clin Med Res 2007;5:8–16. doi:10.3121/cmr.2007.724)
Michael D. Caldwell, MD, PhD; Richard L. Berg, MS; Kai Qi Zhang, BS; Ingrid Glurich, PhD; John R. Schmelzer, PhD; Steven H. Yale, MD; Humberto J. Vidaillet, MD; and James K. Burmester, PhD†
The original article to which this correction refers was published in the March 2007 issue of Clinical Medicine & Research (Clin Med Res 2007;5:8–16. doi:10.3121/cmr.2007.724).
The authors reported the groups were incorrectly labeled in the originally published version of Figure 1A ▶. The correct group labels are (left to right) *1/*1, *1/*2, *1/*3, *2/*2, *2/*3, *3/*3. These are the same groups that are further partitioned in Figure 1B ▶. A corrected figure is provided here (see corrected Figure 1A ▶).
Correction Figure 1A.
Stable coumadin dose by genotype. Distribution of weekly stabilizing warfarin dose in relation to (A) CYP2C9 and (B) CYP2C9 and VKORC1 genotypes. The CYP2C9 genotype is labeled as *1/*1, *1/*2, *1/*3, *2/*2, *2/*3 and *3/*3. For (B), within each CYP2C9 genotype, the VKORC1 genotype is shown as GG, GC or CC. [see original Figure 1 to view panel B].
† Address correspondence to: James K. Burmester, PhD; Center for Human Genetics, Marshfield Clinic Research Foundation, 1000 North Oak Avenue, Marshfield, WI 54449. Telephone: 715-389-4368; Fax: 715-389-3808; Email:burmester.jim@mcrf.mfldclin.edu.